Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cheaper liver dialysis machine could be just as effective

NCT ID NCT02310542

Disease control Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study compares two machines that clean the blood of toxins when the liver fails: MARS (a standard system) and SPAD (a simpler, cheaper alternative). Thirty-four patients with severe liver failure will try both machines in random order. The goal is to see if SPAD works as well as MARS at removing bilirubin and other toxins.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
albumin dialysis (MARS or SPAD device)
What this could lead to
If one system works as well as the other, it could offer a simpler, less expensive way to support liver function in critically ill patients.
What could go wrong
This is a small, early-stage study with only 34 participants, so results may not apply broadly. Both systems are temporary supports, not cures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

34 people

The number who actually took part.

Start date

Dec 2011

Finished

Sep 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * severe hepatic failure on acute liver failure or acute on chronic liver failure * hyperbilirubinemia (total plasmatic bilirubin level above 250µmol/L) * hepatic encephalopathy or pruritus or hepatorenal syndrome. * waiting for liver function recovery or liver transplantation * Signed written informed consent by patient or patient's legally appointed representative or reliable person * affiliation to social security Exclusion Criteria: * contraindication to extra-renal epuration * hypersensibility to albumin or excipients * patients for whom 2 albumin dialysis treatment cannot be considered

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic hepatic failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute liver failure chronic liver failure End Stage Liver Disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic hepatic failure Liver failure, acute

Contacts and locations

Locations

  • Hôpital de la Croix Rousse - Service de réanimation chirurgicale

    Lyon, 69317, France